Home (Related)
Health Centers (Related) HealthandAge Network (Related)
Caregivers' Center (Related) Men's Health (Related) Women's Health (Related)
News (Related) Articles (Related) Questions & Answers (Related) Tools (Related)
Primer on Aging (Related)
RSS (Related)
Bookmark this Page (Related) Choose Font Size Normal Large Extra Large
[
Home (Related) >
IBS Treatment Updated
]
IBS Treatment Updated
Summarized by Robert W. Griffith, MD (Related)
June 14, 2007
Summary
The British Society of Gastroenterology has issued guidelines for diagnosing and treating irritable bowel syndrome (IBS). Here's a digest of the main recommendations.
Introduction
New drugs introduced in the last 10 years for both types of irritable bowel syndrome (IBS) have run into side-effect problems. Tegaserod (Zelnorm ® ), which is effective in constipation-type IBS, has recently been withdrawn in the USA, at the request of the FDA: the authorities were concerned about a slight increase in the number of heart attacks, strokes and severe cardiac chest pain (angina) in patients taking the drug, compared with those taking placebo. In 2000, alosetron (Lotronex ® ) was withdrawn, after studies linked it to an increased risk of severe constipation and ischemic colitis; it has been re-introduced, with strong warnings about possible side effects.
A review of current thinking on treatment is clearly in order. The British Society of Gastroenterology has issued guidelines for diagnosing and treating IBS, which have been published in the medical journal Gut . Here's a digest of the main recommendations.
Diagnosis of IBS
IBS can be classified according to the predominant bowel habit - diarrhea or constipation. In the diarrhea type, few investigations are needed to make the diagnosis; a careful history will usually suffice (abdominal pain relieved by defecation, looser stool, and change in frequency). Patients who have IBS with constipation can have sensitive intestines that are far less tolerant, leading to pain and a great deal of discomfort from even minor constipation. Self-treatment may cause diarrhea, causing confusion about the type of IBS, so that here, too, a careful history is important.
Features that may help the diagnosis include frequent doctor visits for medically unexplained symptoms and a history of anxiety or depression. Somatization - the conversion of anxiety into physical symptoms - is common with IBS.
Certain symptoms are called "alarm symptoms" and warrant further investigation, such as a full white blood cell count, an erythrocyte sedimentation rate, and celiac serology to exclude celiac disease. They include:
Age over 50 Symptom duration less than 6 months Male sex Weight loss Symptoms at night Family history of colon cancer Rectal bleeding Anemia Recent antibiotic use
After the diagnosis (definite or tentative) has been conveyed, the patient should be given the opportunity to discuss their fears; for instance, the belief that their symptoms reflect more serious disease.
Treatment
Because IBS is such a diverse disease, no single treatment benefits more than 20% of patients. This means the focus of management should be to target specific treatments to those who will benefit.
Dietary management should start with a detailed dietary history, followed by moderation of excessive consumption of any one component. For instance, if lactose, wheat, and/or insoluble fiber intake seems to be above average, trial exclusion of one or all of these may be beneficial.
Psychological therapy should be in the forefront if anxiety, depression, or panic attacks are prominent features. Relaxation therapy, cognitive behavioral therapy1 1 and psychodynamic interpersonal therapy2 2 can all help some patients cope with their disease, and hypnotherapy has been shown to be effective in difficult cases.
Medications
In general, the effectiveness of drugs in IBS is somewhat disappointing, compared with their clear-cut benefits in other diseases. The following medications have shown greater benefits than placebo for different symptoms:
Pain is improved by antispasmodics, such as such as dicyclomine (Bentyl ® ), hyoscyamine (Levsin ® ), and belladonna/phenobarbital (Donnatal ® ).
Constipation-predominant IBS can be improved by taking soluble fiber supplements (e.g. Metamucil ® ), but bran and insoluble fiber may worsen symptoms. Drugs of the 5HT-4 agonist class3 3 improve constipation and bloating, but the withdrawal of tegaserod (Zelnorm) sets a high hurdle for developers of new candidates, as the increase in side effects was so small that impossibly large clinical trials would be required.
Diarrhea-predominant IBS responds to 5HT-3 antagonists, but here again rare side effects (e.g. colitis) with alosetron (Lotronex) casts a shadow on this class of drugs for use in IBS. Loperamide (Imodium ® ) may reduce urgency of defecation and frequency, but increase discomfort and pain.
Tricyclic antidepressant drugs improve pain and help with psychological symptoms; selective serotonin inhibitors (SSRIs), which are also antidepressants, improve global symptoms in many cases.
Conclusions
IBS is a common disorder and has an important negative impact on quality-of-life and social functioning in many patients. However, it is not known to be linked to the development of serious disease or to affect mortality.
Treatment is largely unsatisfactory, as there is no good way to determine which patients will respond to specific therapies. The British review concludes that more research is needed in this direction.
Source Spiller R, et al. Guidelines for the management of Irritable Bowel Syndrome. Gut.2007; 0: gut.2007.119446v1
Footnotes
1. (Related) Cognitive behavior therapy combines two very effective kinds of psychotherapy. Cognitive therapy shows you how certain thinking patterns are causing your symptoms, by giving you a distorted picture of what's going on, and making you anxious, depressed or angry. Behavior therapy helps you weaken the connections between troublesome situations and your habitual reactions to them, such as fear, depression, or anger.
2. (Related) Psychodynamic interpersonal therapy emphasizes the ways in which a person's current relationships and social context cause or maintain symptoms, rather than exploring the deep-seated sources of the symptoms. Its goals are rapid symptom reduction and improved social adjustment.
3. (Related) Serotonin or 5-hydroxytryptamine (5-HT), acting particularly through the 5-HT3
and 5-HT4 receptors, plays a significant role in the control of gastrointestinal
motility, sensation and secretion.
Related Links
Treating IBS by Hypnosis? (Related)
Yogurt's Effects on Intestinal Conditions (Related)
A Psychologist has Irritable Bowel Syndrome - Part 1: Understanding the Problem (Related)
Please take a moment to give us your comments. For questions about Health matters you may check our "Questions & Answers" (Related) Portal and Service.
AFGHANISTAN ALBANIA ALGERIA AMERICAN SAMOA ANDORRA ANGOLA ANGUILLA ANTARCTICA ANTIGUA AND BARBUDA ARGENTINA ARMENIA ARUBA AUSTRALIA AUSTRIA AZERBAIJAN BAHAMAS BAHRAIN BANGLADESH BARBADOS BELARUS BELGIUM BELIZE BENIN BERMUDA BHUTAN BOLIVIA BOSNIA AND HERZEGOVINA BOTSWANA BOUVET ISLAND BRAZIL BRITISH INDIAN OCEAN TERRITORY BRUNEI DARUSSALAM BULGARIA BURKINA FASO BURUNDI CAMBODIA CAMEROON CANADA CAPE VERDE CAYMAN ISLANDS CENTRAL AFRICAN REPUBLIC CHAD CHILE CHINA CHRISTMAS ISLAND COCOS (KEELING) ISLANDS COLOMBIA COMOROS CONGO CONGO, THE DEMOCRATIC REPUBLIC OF THE COOK ISLANDS COSTA RICA COTE D'IVOIRE CROATIA CUBA CYPRUS CZECH REPUBLIC DENMARK DJIBOUTI DOMINICA DOMINICAN REPUBLIC ECUADOR EGYPT EL SALVADOR EQUATORIAL GUINEA ERITREA ESTONIA ETHIOPIA FALKLAND ISLANDS (MALVINAS) FAROE ISLANDS FIJI FINLAND FRANCE FRENCH GUIANA FRENCH POLYNESIA FRENCH SOUTHERN TERRITORIES GABON GAMBIA GEORGIA GERMANY GHANA GIBRALTAR GREECE GREENLAND GRENADA GUADELOUPE GUAM GUATEMALA GUINEA GUINEA-BISSAU GUYANA HAITI HEARD ISLAND AND MCDONALD ISLANDS HOLY SEE (VATICAN CITY STATE) HONDURAS HONG KONG HUNGARY ICELAND INDIA INDONESIA IRAN, ISLAMIC REPUBLIC OF IRAQ IRELAND ISRAEL ITALY JAMAICA JAPAN JORDAN KAZAKHSTAN KENYA KIRIBATI KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF KOREA, REPUBLIC OF KUWAIT KYRGYZSTAN LAO PEOPLE'S DEMOCRATIC REPUBLIC LATVIA LEBANON LESOTHO LIBERIA LIBYAN ARAB JAMAHIRIYA LIECHTENSTEIN LITHUANIA LUXEMBOURG MACAO MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF MADAGASCAR MALAWI MALAYSIA MALDIVES MALI MALTA MARSHALL ISLANDS MARTINIQUE MAURITANIA MAURITIUS MAYOTTE MEXICO MICRONESIA, FEDERATED STATES OF MOLDOVA, REPUBLIC OF MONACO MONGOLIA MONTSERRAT MOROCCO MOZAMBIQUE MYANMAR NAMIBIA NAURU NEPAL NETHERLANDS NETHERLANDS ANTILLES NEW CALEDONIA NEW ZEALAND NICARAGUA NIGER NIGERIA NIUE NORFOLK ISLAND NORTHERN MARIANA ISLANDS NORWAY OMAN PAKISTAN PALAU PALESTINIAN TERRITORY, OCCUPIED PANAMA PAPUA NEW GUINEA PARAGUAY PERU PHILIPPINES PITCAIRN POLAND PORTUGAL PUERTO RICO QATAR REUNION ROMANIA RUSSIAN FEDERATION RWANDA SAINT HELENA SAINT KITTS AND NEVIS SAINT LUCIA SAINT PIERRE AND MIQUELON SAINT VINCENT AND THE GRENADINES SAMOA SAN MARINO SAO TOME AND PRINCIPE SAUDI ARABIA SENEGAL SEYCHELLES SIERRA LEONE SINGAPORE SLOVAKIA SLOVENIA SOLOMON ISLANDS SOMALIA SOUTH AFRICA SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS SPAIN SRI LANKA SUDAN SURINAME SVALBARD AND JAN MAYEN SWAZILAND SWEDEN SWITZERLAND SYRIAN ARAB REPUBLIC TAIWAN, PROVINCE OF CHINA TAJIKISTAN TANZANIA, UNITED REPUBLIC OF THAILAND TIMOR-LESTE TOGO TOKELAU TONGA TRINIDAD AND TOBAGO TUNISIA TURKEY TURKMENISTAN TURKS AND CAICOS ISLANDS TUVALU UGANDA UKRAINE UNITED ARAB EMIRATES UNITED KINGDOM UNITED STATES UNITED STATES MINOR OUTLYING ISLANDS URUGUAY UZBEKISTAN VANUATU VENEZUELA VIET NAM VIRGIN ISLANDS, BRITISH VIRGIN ISLANDS, U.S. WALLIS AND FUTUNA WESTERN SAHARA YEMEN YUGOSLAVIA ZAMBIA ZIMBABWE Other Select your Country...
Comments (English only)
Please send me the free
healthandage.com bimonthly newsletter
How do you rate this article?
Quality
Excellent
Good
Poor
Level
Too difficult
Just right
Too simple
Copyright © 2006. All rights reserved. [ Privacy Policy (Related) | Terms of Use (Related) | About Us (Related) | Site Map (Related) ]
No comments:
Post a Comment